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Due to rapid technological advances, various types of genomic and proteomic data with diﬀerent sizes, formats, and structures
have become available. Among them are gene expression, single nucleotide polymorphism, copy number variation, and protein-
protein/gene-gene interactions. Each of these distinct data types provides a diﬀerent, partly independent and complementary,
view of the whole genome. However, understanding functions of genes, proteins, and other aspects of the genome requires more
information than provided by each of the datasets. Integrating data from diﬀerent sources is, therefore, an important part of
current research in genomics and proteomics. Data integration also plays important roles in combining clinical, environmental,
and demographic data with high-throughput genomic data. Nevertheless, the concept of data integration is not well deﬁned in
the literature and it may mean diﬀerent things to diﬀerent researchers. In this paper, we ﬁrst propose a conceptual framework
for integrating genetic, genomic, and proteomic data. The framework captures fundamental aspects of data integration and is
developed taking the key steps in genetic, genomic, and proteomic data fusion. Secondly, we provide a review of some of the most
commonly used current methods and approaches for combining genomic data with focus on the statistical aspects.
Copyright © 2009 Jemila S. Hamid et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Background
In recent years, increasing amounts of genomic data have
become available. The size, type, and structure of these data
have also been growing at an unprecedented rate. Gene
expression, single nucleotide polymorphisms (SNP), copy
number variation (CNV), proteomic, and protein-protein
interactions are some examples of genomic and proteomic
data produced using high throughput technologies such as
microarrays[1], array comparative hybridization, aCGH [2],
and mass spectrometry [3]. Each of these distinct data types
provides a diﬀerent, partly independent and complementary
view of the whole genome. However, elucidation of gene
function and other aspects of the genome may require
more information than is provided by one type of data.
The amount and type of biological data are expected to
increase even further (e.g., methylation, alternative splicing,
transcriptomic, metabolomic, etc.). This proliferation of
experimental data makes systematic integration an impor-
tant component of genomics and bioinformatics [4]. Data
integration is increasingly becoming an essential tool to
cope with the ever increasing amount of data, to cross-
validate noisy data sets, and to gain broad interdisci-
plinary views of large genomic and proteomic data sets.
Instances of combining and synthesizing data have increased
considerably in the last several years and the need for
improved and standardized methods has been recognized
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In functional genomics, for example, one is interested in
deﬁning the function of all the genes in the genome of an
organism. Deﬁning functions of genes is a daunting task and
achieving this goal requires integrating information from
diﬀerent experiments [8]. Similarly, classifying a protein as a
membraneproteinbasedonproteinsequencesisanontrivial
task and has been the subject of much previous research,
and it has been demonstrated that incorporating knowl-
edge derived from aminoacid sequences, gene expression
data, and known protein-protein interactions signiﬁcantly
improves classiﬁcation performance compared to any single
type of data [9].
Theneedforintegrationofheterogeneousdatameasured
on the same individuals arises in a wide range of clinical
applications as well. In this regard, the best example is
perhaps the challenge that cancer researchers and clinicians
face in the diagnosis, treatment, and prognostication of this
complex disease. The clinical management of cancer is cur-
rently based for the most part on information accumulated
from clinical studies [10]. However, cancer is thought to
be primarily caused by random genetic alterations, and as
such genomic data such as gene expression and protein data
can be used to classify tumors into subtypes, and thus may
have the potential to improve the clinical management of
cancer.
Data integration also plays an important role in under-
standing environment-genome interactions in toxicoge-
nomics, a discipline where one investigates how various
genes respond to environmental toxins and stressors, and
how these factors modify the function and expression of
genes in the genome [11]. The contribution of diﬀerent
sources of data (such as genomics, proteomics, and SNP) in
advancing the ﬁeld of toxicology is discussed by Patel et al.
[11].
Anothermorecommontypeofdataintegrationrelatesto
combining similar types of data across diﬀerent studies. This
can,forexample,bedonethroughmeta-analyticapproaches.
Forinstance,withtheincreasingnumberofpubliclyavailable
independent microarray datasets, it is important to combine
studies that address similar hypotheses. Such analyses have
proven to be very useful in several applications (see, e.g.,
Rhodes et al. [12]).
There are a number of challenges in the context of high
biology genetic and genomic studies. The challenges may be
of conceptual, methodological, or practical nature and may
relatetoissuesthatariseduetoexperimental,computational,
or statistical complexities. For example, genomic data are
often subject to varying degrees of noise, the curse of high
dimensionality, and small sample sizes. One may, therefore,
beneﬁt from integrating clinical, genomic, proteomic data
along with environmental factors.
Integrating data from diﬀerent sources brings many
challenges. In dealing with heterogeneous data, for example,
one needs to convert data from diﬀerent sources into a
common format and common dimension. Genomic data
arises in the form of vectors, graphs, or sequences, therefore
it is essential to carefully consider strategies that best capture
the most information contained in each data type before
combining them.
M o r e o v e r ,d a t af r o md i ﬀerent sources might have diﬀer-
entqualityandinformativity.Probedesignandexperimental
conditions are known to inﬂuence signal intensities and
sensitivitiesformanyhigh-throughputtechnologies[13,14].
Evenforsimilardatatypes,datafromdiﬀerentsourcesmight
have diﬀerent quality depending on the experimental con-
ditions that generated the data. In microarray experiments,
for instance, lack of standards generates heterogeneous
datasets for which direct comparison and integration is
not possible [15]. Data from diﬀerent sources might also
have diﬀerent informativity even if their quality is good
a n dr e l i a b l e ;t h u so n es o u r c eo fd a t am i g h tg i v eu sm o r e
information than the other in answering the biological ques-
tion of interest. For example, gene expression microarray
data is expected to provide more information in recog-
nizing ribosomal proteins than protein-protein interaction
data. However, expression data is not expected to pro-
vide much information in identifying membrane proteins
[9].
The overarching goals of data integration are to obtain
more precision, better accuracy, and greater statistical power
than any individual dataset would provide. Moreover,
integration can be useful in comparing, validating, and
assessing results from diﬀerent studies and datasets. It is
likely that whenever information from multiple independent
sources agree, it is more likely for the ﬁndings to be
valid and reliable than information from a single source
[8].
Current methods for data integration in general and
combining genomic and genetic data in particular are scat-
tered in the literature and lack solid conceptual framework.
Putting them under a single framework would bring more
understanding and clarity for the research community. With
this background in mind, the objective of this paper is
two fold. The ﬁrst objective is to introduce a conceptual
framework for integrating genomic and genetic data. This
framework, which can be adapted to most data integration
tasks in the life sciences, can serve as a guideline for
understanding key issues and challenges that arise in data
integration in genetics and genomics. We also believe that
the framework we introduce here can be used for motivating
and developing improved methods for integrating genomic
and genetic data. The second purpose of the paper is to
review some of the most commonly used current methods
andapproachesforcombininggenomicdata.Thereviewsare
done from a statistical perspective and our discussions are
focused more on methodological issues and challenges. This
could be useful in identifying research directions and might
lead to improved methodologies in combining genomic
data.
The paper is organized as follows. In Section 2,w e
provide a conceptual framework for data integration and
discuss key concepts regarding this framework. In Section 3,
we discuss some of the methods used in integrating similar
data types, and methods for integrating heterogeneous data
types, including integrating statistical results with biological
data, are reviewed in Section 4. A brief discussion and some
highlights for future research directions are presented in
Section 5.Human Genomics and Proteomics 3
2. A Conceptual Framework for
DataIntegration
The concept of data integration is not well deﬁned in the
literature and it may mean diﬀerent things for diﬀerent
people. For instance, Lu et al. deﬁned data integration, in the
context of functional genomics, as the process of statistically
combining data from diﬀerent sources to provide a uniﬁed
view of the whole genome and make large-scale statistical
inference [16]. We view data integration in a much broader
context so that it includes not only combining of data using
statistical approaches, but also data fusion with biological
domain knowledge using a variety of bioinformatics and
computational tools.
In this section, we propose a conceptual framework
for integrating genomic and genetic data. This framework
attempts to capture the fundamental aspects of data inte-
gration and is developed taking the key steps involved
in genomic and genetic data fusion into consideration. A
ﬂowchart describing the conceptual framework is given in
Figure 1. Below we brieﬂy discuss each of the three key com-
ponents of data integration: posing the statistical/biological
problem; recognizing the data type; stage of integration.
2.1. Posing the Statistical/Biological Problem. Identifying the
statistical or biological problem is the ﬁrst step in any
statisticalresearchingeneralandingenomicandgeneticdata
fusion in particular. Diﬀerent directions in the framework
and methods are followed depending on the biological
question of interest. For example, one might merge pre-
processed and transformed (independently or in parallel)
microarraydatafromdiﬀerentlabs(experiments)toincrease
sample size and answer a scientiﬁc question related to the
detection of diﬀerentially expressed genes across a range of
experimental conditions [17]. Traditional biological research
questions are for the most part hypothesis-driven where
one performs experiments to answer speciﬁc biological
hypotheses. However, current high throughput data have a
wealth of information in answering many other statistical or
biological questions. In modern genomics, it is increasingly
accepted to generate data in a relatively hypothesis-free
setting where diﬀerent questions can be posed on the pool of
data and data are mined with a variety of computational and
statistical tools with the hope of discovering new knowledge.
2.2. Data Types. Current data integration methods fall
into two diﬀerent categories—integrating similar data types
(across studies) or integrating heterogeneous data types
(across studies as well as within studies). Once we identify
the biological or statistical question, we can ask ourselves
what type of data we have. Classifying data as similar
or heterogeneous is not an easy task. In this paper, we
consider data as of “similar type” if they are from the same
underlying source, that is, if they are all gene expression,
SNP, protein, copy number, sequence, clinical, and so on.
We refer to data as of the “heterogeneous type” if two or
more fundamentally diﬀerent data sources are involved. One
might,forexample,wanttodevelopapredictivemodelbased
on diﬀerent genomic data (SNP, gene expression, protein,
sequence) as well as clinical data. These data sets might have
diﬀerent structures, dimensions, and formats. Some of them
aresequences,somegraphs,andyetothersmaybenumerical
quantities. Integration of heterogeneous data, therefore,
entails converting each of the separate sources into common
structure, format, and dimension before combining them.
Whether data are of similar or heterogeneous type, the
issue of quality and informativity is of great importance as
well. Each data source is subject to diﬀerent noise levels
depending on the technology, the platform, the lab, and
many other systematic and random errors. Therefore, the
concept of weighting the data sources with quality and/or
informativity scores becomes an essential component of the
framework.
2.3. Stages of Integration. Data from diﬀerent sources can be
integrated at three diﬀerent stages—early, intermediate, or
late. The stage at which data are combined depends on the
biological question, the nature, and type of data as well as
the availability of original data. Regardless of the biological
question at hand (e.g., test for diﬀerential expression, class
discovery, class prediction, gene mapping, etc.) one might,
for example, merge data from diﬀerent studies, experiments,
or labs to increase sample size. This is considered as
integration at early stage. Merging weighted (by quality
and/or informativity scores) data is also considered as early
integration. This is because attaching of weights to the
data does not change the general format and nature of the
resulting data. However, the integration is considered as
intermediate if we transform individual data sources into
another format before we combine them. For example, in
class prediction problems, one might convert the data into
similarity matrices such as the covariance or correlation
matrix and combine these similarity matrices for better
prediction. Unlike the early stage integration, original data
sets from the diﬀerent sources are converted to a common
format and dimension. Integration is considered to be at a
late stage if ﬁnal statistical results from diﬀerent studies are
combined. This stage includes, among others, meta-analytic
techniques where one typically combines eﬀect sizes or p
values across studies.
2.4. Preprocessing. Genomic data are subject to diﬀerent
noises and errors, and a number of critical steps are
requiredtopreprocessrawmeasurements.Animportantstep
considered in our framework, therefore, is preprocessing.
However, this is not the main focus of this paper and hence
we do not go into details. We refer the reader to [18, 19]f o r
more details.
Preprocessing precedes data integration and may include
background correction, normalization, and quality assess-
ment of data from high throughput technologies [19].
Approaches for preprocessing vary depending on the type
and nature of data. Preprocessing methods for microarray
data are, for example, diﬀerent from that for array CGH
or proteomic data. Moreover, data from diﬀerent tech-
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Figure 1: Conceptual framework for data integration in genetics and genomics.
Forexample,diﬀerentapproachesareutilizedforpreprocess-
ing cDNA and Aﬀymetrix gene expression microarray data
[18, 19].
Data preprocessing can be done at any step of the data
integration process. Some form of preprocessing is almost
always done at the initial stage [13]. However, genomic data,
in most cases, has to go through some sort of preprocessing
before doing any statistical analysis to answer the biological
question of interest. There is a large body of literature
on this topic, and several ways of preprocessing high
throughput data have been proposed [18, 19]. Approaches,
bothgraphicalandstatistical,arealsoavailableforvisualizing
and checking if data needs to be preprocessed. In microarray
studies, the standard procedure for researchers is to use
preprocessed data as the starting point; however, this has
prevented many researchers from carefully considering their
preprocessing methods [20].
Data matching is another preprocessing step that needs
to be taken into account before combining data from high
throughput technologies. In gene or marker speciﬁc data
integration, a major challenge in pooling information from
diﬀerent data sources can be partly due to the fact that
measurements are obtained by diﬀerent technologies or they
measure diﬀerent aspects of the same underlying quantity.
For example, Aﬀymetrix uses diﬀerent numbers of probes
to measure the same gene in diﬀerent chip types. Therefore,
it is impossible to get comparable gene expression levels
across diﬀerent chip types simply based on gene identiﬁers
since they used diﬀerent probe sequences for the given
target probes. Mecham et al. [21] proposed a sequence-
based matching of probes instead of gene identiﬁer-based
matching. The results showed that at diﬀerent levels of
the analysis (e.g., gene expression ratios), cross-platform
consistency is signiﬁcantly improved by sequence-based
matching.
Combining data from diﬀerent genotyping projects
presents a problem in that diﬀerent marker sets are used
for diﬀerent arrays. For example, out of the approximately
1 million SNPs on each of the Aﬀymetrix Human SNP
6.0 and Illumina Human1M arrays, only about 250,000
SNPs are common to both assays [22]. To overcome this
diﬃculty, genotype imputation algorithms, such as MACH
[23], IMPUTE [24], and fastPHASE [25], have been devel-
oped to impute alleles at ungenotyped markers, based on
the genotypes of surrounding markers. In summary, the
preprocessing step can hugely aﬀect the properties of the
ﬁnal statistical summaries and hence the statistical results.
Therefore, methods for preprocessing must be chosen with
care.
3.IntegratingSimilarDataTypes
Although posing the statistical/biological problem is the ﬁrst
step in any study involving data integration, data integration
in general is divided into two broad categories: integration
of similar data types and integration of heterogeneous data
types. In this section, we give a review of some of the current
methods available for integrating similar data types. Similar
data types have been combined to answer diﬀerent biological
questions, and approaches for integrating such data at early,
intermediate, or late stages have been proposed in literature.
However, these approaches are in general meta-analytic
methods. Some examples from the published literature
that can serve as illustration for data integration conceptsHuman Genomics and Proteomics 5
corresponding to diﬀerent biological/statistical questions,
data types, and stages of integration are highlighted in
Table 1.
3.1. Integration of Linkage Studies. Linkage analysis is a
gene mapping technique which is based on the process
of recombination, or the crossing over of parental chro-
mosomes when forming gametes which will eventually
b ep a s s e do nt oo ﬀspring. In order to observe or infer
recombination events, families are required to reconstruct
the transmission of alleles and phenotypes through several
generations. Highly polymorphic markers are genotyped
either in a region of interest, based on previous knowledge
or hypotheses (candidate gene mapping), or across the entire
genome (genome-wide scans). Linkage analysis looks for the
cosegregation of a marker and the trait of interest in each
family, and one way to assess linkage statistically is through
the log odds, or LOD score:
LOD = log10(L(data|theta)/L(data|theta = 0.5)),
where L is a likelihood function and theta is a measure
of the amount of recombination between the marker and
the trait. The LOD score can be maximized over a grid
of theta values, but is usually just computed at ﬁxed theta
intervals. Scores for each family are summed, and an overall
LOD score > 3 (i.e., likelihood ratio than 1000:1 odds) is
generally considered to be a signiﬁcant evidence for linkage.
For further details, the interested reader is referred to an
excellent textbook in [30].
Linkage analysis has been very successful for rare
Mendelian disorders, that is, diseases where the variant is
associated with a large increase in risk, and usually only one
variant is responsible for the phenotype. However, in the
case of complex traits, where multiple variants are likely to
contribute, each with more modest risk, large collections
of families need to be genotyped and phenotyped to have
modest power to detect linkage, which is a costly and
time-consuming undertaking. Combining information from
several scans can, therefore, help overcome these diﬃculties.
Three main strategies have been used to integrate linkage
data: pooling of datasets (integration at an early stage),
combining linkage statistics or P-values (integration at a late
stage), and combining eﬀect sizes (also integration at a late
stage).
When the raw data from all studies are available, the
most powerful approach is to simply pool the datasets and
analyze this large dataset as if it were one study, termed a
“mega analysis” [31]. This assumes that the same markers
are common to all studies, and that there were identical
ascertainment strategies and similar allele frequencies in the
populations from which the samples were derived from. It is
also equivalent to simply sum the LOD scores from various
studies, under the same restrictions [32]. Since it is rare to
have identical marker maps across studies, methods to allow
LOD score calculations at arbitrary marker positions were
developed to overcome this problem [33, 34]. An alternative
method,knownastheposteriorprobabilityoflinkage(PPL),
puts the question of linkage in a Bayesian context, which
allows the posterior distribution of linkage, given the data,
to be updated as new data and studies are accumulated [35].
In the more common situation when the raw data is
not available, perhaps the simplest method to combine




log pi,( 1 )
where k is the number of studies, pi is the P-value obtained
from study i. The statistic S is asymptotically distributed as
a chi-square with 2k degrees of freedom. This procedure
w a su s e db yA l l i s o na n dH e o[ 37] to identify regions linked
to obesity, and a modiﬁed version was used by Badner and
Gershon [38] for autism studies. The null hypothesis for this
testisthatnoneofthestudiesshowsigniﬁcantresults,against
the alternative that at least one is signiﬁcant. This may not
be the question that a researcher is interested in asking; a
more relevant question may be whether all studies support
a common hypothesis. In this situation, Rice (1990) [39]
suggests that a summary statistic based on the mean of the
normal-transformed P-values may be more appropriate.
In the Fisher method, a single P-value per study is
used. However, in the context of a genome-wide scan, many
markers are genotyped, and so many LOD scores or P-
values are calculated. To address this issue, Wise et al. [40]
proposed a method called genome search meta-analysis
(GSMA) which ranks signiﬁcant results within each study,
and sums the ranks for each region across all studies. The
ranks can be weighted by study characteristics such as the
number of pedigrees or the number of markers. This test will
detect regions which are implicated in several studies.
The use of P-values from individual studies generally
precludes the estimation of average eﬀect sizes, which can
be of interest in linkage studies. These estimates are the
main goal of most standard meta-analyses. Li and Rao
[41] proposed the use of a random eﬀects model [42]t o
combine regression coeﬃcients from a linear model of the
squared trait diﬀerences as the dependent variable, and the
proportion of alleles shared identical by descent (IBD) at
a marker for sibling pairs as the independent variable. The
model was also applied using the proportion of alleles shared
IBD directly as the measure of eﬀect size [43]. Along with
an overall estimate of eﬀect size, the random eﬀects model
has the advantage of being able to test for and control for
diﬀerences in eﬀect sizes across studies (sometimes referred
to as heterogeneity).
3.2. Integration of Genetic Association Studies. In the past
few years, it has been shown that genome-wide association
studies have strong power to identify genetic determinants
for common and rare diseases. Due to the high cost of
performing these types of studies, it becomes more and
more important to integrate evidence from multiple studies
in characterizing the genetic risks of these diseases. Meta-
analysescanoﬀerbothenhancedpowertodetectassociations
and increased precision of estimates of its magnitude. There
are two major methods with focusing on late stage integra-
tion. One is combining eﬀect sizes, primarily the odds ratio6 Human Genomics and Proteomics
Table 1: Some illustrative examples for integrating similar and heterogeneous genomic, genetic, and proteomic data.
Data types Biological/statistical
question
Stages of integration Example/comments
Sample classiﬁcation Early
Jiang et al. [17] integrated two
Aﬀymetrix data sets; each data set was
ﬁrst distribution transformed and two
data sets were then merged together.
Similar data types Diﬀerential gene
analysis
Late
Rhodes et al. 2002 [12] integrated two
cDNA and two Oligo data sets; P-value
was ﬁrst calculated for each gene in
each study and Fisher’s method was
used to combine the P-values.
Gene mapping Late
Ioannidis et al. [26] integrated two
Aﬀymetrix and one Illumina SNP data
sets; odds ratio (OR) was ﬁrst
calculated for each SNP in each study





Adler et al. [27] integrated aCGH and
gene expression data sets; association
analysis between two datasets was
made in ampliﬁcation and deletion
regions.
Heterogeneous data types Protein classiﬁcation Intermediate
Lanckriet et al. [9] integrated
sequence, interaction, and expression;
a kernel matrix was ﬁrst generated for
each data set and combined using
optimal weights.
Gene mapping Intermediate
McCaroll and Altshuler (2007) [28]
integrated genotype and copy number
variation data; copy number variation





Al-Shahrour et al. [29] integrated gene
expression and biological domain
information; gene-speciﬁc test statistic
was ﬁrst calculated, which was then
integrated with biological domain
information to evaluate function
enrichment.
(OR) and another is to combine P-values [26, 44, 45]. The
eﬀectsizebasedmethodcanbeﬁxedeﬀectsorrandomeﬀects
models. For example, Ioannidis et al. [26]a p p l i e dar a n d o m
eﬀects model to combine all data sets generated in three
stages from three genome-wide association (GWA) studies
on type 2 diabetes. Details of the design and populations of
thesestudieshavebeenpresentedintheoriginalpublications
[46–48]. Ioannidis et al. [26] selected 11 polymorphisms
suggested as susceptibility loci for type 2 diabetes in at
least one of the three studies. They found 5 of the 11
genetic variants have moderate to very large heterogeneity
across studies. Therefore, they used random eﬀects calcula-
tions incorporating between study heterogeneity for these
5 polymorphisms and found more conservative P-values
for the summary eﬀects compared with the ﬁxed eﬀects
calculations. Instead of focusing on meta-analysis of only
identiﬁed polymorphisms, Zeggini et al. [45] applied ﬁxed
eﬀectsmodel and combingP-valuemethods tometa-analyze
the same data sets, they detected at least six previously
unknown loci with robust evidence for association.
3.3. Integration of Gene Expression Microarray Studies.
Microarrays have been widely used in identifying diﬀer-
entially expressed genes [48, 49] and for building gene
expression proﬁle-based predictors for disease outcome
diagnosis [50–54]. Although some of these studies have led
to promising results [51], it is diﬃcult to directly compare
the results obtained by diﬀerent groups addressing the same
biological problem. This is because laboratory protocols,
microarray platforms, and analysis techniques used in each
study may not be identical [55, 56]. Moreover, most indi-
vidual studies have relatively small sample sizes, and henceHuman Genomics and Proteomics 7
predictive models trained by individual studies using cross-
validation are prone to over-ﬁtting, leading to prediction
accuracies that may be less robust and lack generalizability
[57]. Recent studies show that systematic integration of
gene expression data from diﬀerent sources can increase
statistical power in detecting diﬀerentially expressed genes
while allowing for an assessment of heterogeneity, and may
lead to more robust, reproducible, and accurate predictions
[12, 15, 17, 56, 58–62]. Therefore, our ability to develop
powerfulstatisticalmethodsforeﬃcientlyintegratingrelated
genomic experiments is critical to the success of the massive
investment made on genomic studies. Here, we highlight
some of the strategies that have been used to integrate
microarry gene expression studies.
Combining gene expression data at early and late stages
has been considered by diﬀerent groups. In integrating gene
expression data at an early stage, data sets generated in each
study are ﬁrst preprocessed independently or in parallel,
and then the preprocessed datasets are put together so that
the integrated data set can be treated as one data set. In
this way, the sample size of the study is greatly increased.
Several transformation methods have been proposed to
process gene expression measures from diﬀerent studies
[17, 56, 59, 62]. For example, Jiang et al. [17]t r a n s f o r m e d
the normalized data sets to have similar distributions and
then merged the transformed data sets. Wang et al. [59]
standardized each gene expression level based on the average
expression measurements and the standard errors estimated
from prostate cancer samples. These methods are simple
and in many cases, if the transformation is carefully made,
lead to improved prediction [17]. Nevertheless, there are no
consensus or clear guidelines as to the best way to perform
such data transformations.
At the late stage, results from statistical analyses are
combined using meta-analytic approaches. Similar to the
case of linkage and association gene mapping studies, one of
the popular approaches combines eﬀect sizes from diﬀerent
studies while taking interstudy variability into account when
estimating the overall mean for each gene across studies. For
example, Choi et al. [15] focused on integrating eﬀect size
estimates in individual studies into an overall estimate of
the average eﬀect size. The eﬀect size was used to measure
the magnitude of treatment eﬀe c ti nag i v e ns t u d ya n d
random eﬀects model was adopted to incorporate interstudy
variability. Using the same microarray data sets as those
used by Rhodes et al. [12], Choi et al. [15] demonstrated
that their method can lead to the discovery of small but
consistent expression changes with increased sensitivity and
reliability among the datasets. For each gene, the widely
used eﬀect size measure is the standardized mean diﬀerence
which is obtained by dividing the diﬀerence in average gene
expression between groups of interest by a pooled estimate
of standard deviation [63, 64]. It is well known in microarray
data analysis that the estimated standard deviation might be
unstable when the sample size in each group is small. There-
fore, much eﬀort has been made to overcome the shortfall by
using a penalty parameter for smoothing the estimates using
information from all genes rather than relying solely on the
estimates from an individual gene [4, 65].
As mentioned before, the other meta-analytic technique
commonly used combines P-values across diﬀerent studies.
For example, Rhodes et al. [12, 66] integrated results from
prostate cancer microarray studies which have been per-
formed on diﬀerent platforms. Diﬀerential expression was
ﬁrst assessed independently for each gene in each dataset
using P-values and P-values from individual studies were
combined using Fisher’s method (see also Section 3.1). Their
analysis revealed stronger evidence for statistical signiﬁcance
from the combined analysis than any of the individual
studies separately. Combining P-values can be useful in
detecting eﬀects with improved statistical signiﬁcance, but
this method does not indicate the direction of signiﬁcance
(e.g., up- or downregulation) [67]. Instead of integrating
P-values directly, some studies explored combining the
ranks of the P-values from diﬀerent studies [61, 68]. For
example, DeConde et al. [61] proposed a rank-aggregation
method and combined microarray results from ﬁve prostate
cancer studies where they showed that their approach can
identify more robust diﬀerentially expressed genes across
studies.
The data integration approaches discussed above to
integratemicroarraysareinaquality-unweightedframework
[12, 15, 17, 56, 58, 59, 61, 62, 66]. However, it has been
argued that studies of higher quality give more accurate
estimates and, as a result, should receive higher weight in
the analysis summarizing ﬁndings across studies [69]. In
gene expression microarrays, many genes may be “oﬀ”o r
not detectable in a particular adult tissue, moreover, some
genes may be poorly measured due to probes that are
not suﬃciently sensitive or speciﬁc. Therefore, the signal
strength and clarity will vary across the genes, suggesting
that a quality measurement could highlight strong and clear
signals [70, 71]. How to best measure the quality of a
gene expression measurement and how best to use such a
quality measure are still open research questions. However,
diﬀerent strategies can be considered for incorporating
quality weights into meta-analysis of microarray studies.
For example, a quality threshold can be deﬁned and only
genes that are above this threshold can be included in
the meta-analysis. However, the choice of threshold will be
arbitrary. In a recent study, our group proposed a quality
measure based on the detection P-values estimated from
Aﬀymetrix microarray raw data [60, 70]. Using an eﬀect-size
model, we demonstrated that the incorporation of quality
weights into the study-speciﬁc test statistics, within a meta-
analysis of two Aﬀymetrix microarray studies, produced
more biologically meaningful results than the unweighted
analysis.
4. Integrating Heterogeneous Data Types
Perhaps the most challenging type of data integration is
combining heterogeneous data types. A wide variety of
genomic and proteomic data are becoming available at
an unprecedented pace including data on, but not limited
to, gene expression (quantitative numbers), gene/protein
sequences (strings), gene-gene/protein-protein interactions
(graphs). There is also a growing interest for integration8 Human Genomics and Proteomics
of these and related molecular information with clinical,
laboratory, as well as environmental data. Broadly speaking,
integrating heterogeneous data types involves two steps. The
ﬁrst one is converting data from diﬀerent sources into a
common format. The second, equally important, step is to
combine the data and perform statistical analysis on the
combined data set. Here we survey some of the currently
available approaches for integrating heterogeneous data
types. Some illustrative examples are highlighted in Table 1.
An illustrative ﬂowchart outlining integrative analyses of
heterogeneous data for ﬁnding disease-causing genes is
shown in Figure 2.
4.1.IntegrationofGeneExpressionwithGenotypeData. Gene
expression levels of many genes have been successfully used
to show natural variation in humans [72, 73]. Using regres-
sion analysis where the dependent variables are expression
levels and the independent variables are the genotypes, it
has been shown that expression levels may be inﬂuenced by
single nucleotide polymorphisms [72–75]. These mapping
eﬀorts have identiﬁed quantitative trait loci (QTLs) that may
be in the gene’s own regulatory regions (cis-acting QTLs) as
well as elsewhere in the genome (trans-acting QTLs) using
both linkage [72] and association analysis [73, 74]. For the
associationanalysis,Stranger et al.[74]examinedallpossible
combinations of gene expression phenotype/marker geno-
type combinations, whereas Cheung et al. [73] examined
only gene expression phenotype/genotype combinations
under linkage peaks identiﬁed in the study by Morley et al.
[72].However,itmaybepossiblethatmultiplelociplayarole
in regulating the expression level of a single phenotype. To
this eﬀect, our group used the gene expression and SNP data
reportedinMorley et al.[72]andappliedstepwiseregression
analysis to look for additive eﬀects of the SNPs which
led to the identiﬁcation of cis-a n dtrans-acting loci that
r egulat ege nee xp r essio n[75].Weidentiﬁed manyexpression
phenotypes that have signiﬁcant evidence of association and
linkage to one or more chromosomal regions and showed
that much of the observable heritability in the phenotypes
could be explained by simple SNP associations.
Due to the large number of genes in current high
volume data sets and the existence of various degrees of
noise in the data, integration involving all single-nucleotide
polymorphism (SNP) loci and gene expression phenotypes
may computationally challenging, and results may lack
biological plausibility and interpretability. One promising
approach, that is computationally eﬃcient and can lead to
more robust and interpretable results, is to use methods
that induce sparseness in the integrated solutions where
noisy data are automatically ﬁltered out from analysis. For
example, our group has recently introduced a novel sparse
canonical correlation analysis (SCCA) statistical method,
which allowed us to examine the relationships of many
genetic loci and gene expression phenotypes by providing
sparse linear combinations that include only a small subset
of loci and gene expression phenotypes [76]. The correlated
sets of variables resulting from sparse canonical correlation
analysis are suﬃciently small for biological interpretability
and further follow up. We applied SCCA to data reported in
[72] and identiﬁed small but interesting group of loci and
gene expressions that have maximal correlation across the
two data sources (gene expression and genotypes).
4.2. Integration of Copy Number Variation and Gene Expres-
sion Data. Array CGH (aCGH) microarray technology has
been widely used to identify small or large regions of
ampliﬁcations and deletions along the genome of organisms.
Recent studies have tried to incorporate gene expression
data with aCGH data for ﬁnding disease causing genes
[27, 77–79]. For example, Pollack et al. [77]a n a l y z e dg e n e
expression levels in parallel with copy number aberrations
for the same set of breast tumors. They found that DNA
copy number does have an impact on gene expression levels,
and that a 2-fold change in DNA copy number corresponds
to an average 1.5-fold change in expression level [72–75].
However, it has also been observed that many overexpressed
genes were not ampliﬁed and that not all ampliﬁed genes
were highly expressed, but the small number of genes
that were overexpressed and ampliﬁed could be interest-
ing genes. For example, Platzer et al. [80]m e a s u r e dg e n e
expression levels and DNA copy numbers of colon cancer
samples, and found four chromosomal arms that contained
ampliﬁcations in most samples. Among expression levels
of 2146 transcripts on these arms, only 81 have greater
than 2-fold change in gene expression. They concluded that
chromosomal ampliﬁcations do not result in global over
expression of the genes located at that position. Huang et al.
[79] also found that genomic DNA copy number aberrations
(ampliﬁcation or deletion) appeared not to be parallel with
the corresponding gene expressions in any given samples.
Most of these methods explore the relationship of genomic
DNAcopynumberandgeneexpressionatrelativelythesame
positions of the genes on the genome. However, since it is
known that genes on a chromosome are coregulated [81],
a better way is to determine clusters of signiﬁcantly over or
under expressed genes by taking the chromosome position
into account. This can also be applied on CGH data, and
then a correlation of the clustered or coregulated expression
signatures and copy number data can be determined [78].
4.3. Kernel Based Data Integration for Class Prediction. One
of the novel and most promising methods for integrating
heterogeneous data types are kernel-based statistical meth-
ods. In kernel-based methods, each data set is represented
by a so-called kernel matrix, which essentially constitutes
similaritymeasuresbetweenpairsofentities(genes,proteins,
patients, etc.). In general, these methods are applied in
biological problems related to class discovery and class
prediction. In functional genomics, for example, one is
interested in discovering new functional classes and/or
assigning each gene or protein into already existing classes.
It is also useful in cancer research where one is interested in
discovering new tumor subtypes and/or assigning patients
into already existing tumor types. Kernel-based statistical
methods are tools which have already proven to be powerful




















































Figure 2: An illustrative ﬂowchart for ﬁnding disease causing genes by integrating heterogeneous data.
computational linguistics, and bioinformatics. Their rapid
uptake in these applications is due to their reliability,
accuracy, and computational eﬃciency as well as their ability
to handle various types of data [82].
One can describe kernel-based statistical learning
approaches using two basic steps. The ﬁrst one is choosing
therightkernelforeachdataset.Thisisacrucialanddiﬃcult
step in combining heterogeneous data using kernels. One of
the reasons for the success of kernel methods is that kernel
matrices can be deﬁned for any type of data as well as their
ability to incorporate prior knowledge through the kernel
function [82]. The choice of kernel matrices depends on
what type of data we have (e.g., diﬀusion kernel for graphical
data and sequence-based kernels based on algorithms such
as BLAST for protein sequences) and if the patterns in the
data are linear (linear or standardized linear kernel can be
used) or nonlinear (Gaussian or other nonlinear kernels can
be used). One can also deﬁne diﬀerent kernels on the same
data sets. This allows us to get diﬀerent view of the same
data set and might provide us more information than using
a single kernel. For example, Lanckriet et al. [9]d e ﬁ n e d7
diﬀerentkernelsonthreediﬀerentdatasourcesforpredicting
membrane and ribosomal proteins. The second equally
important and challenging step deals with combining the
kernelsfromthediﬀerentdatasourcestogiveacompleterep-
resentation of available data for a given statistical task. Basic
mathematical operations such as multiplication, addition,
and exponentiation preserve properties of kernel matrices
and hence produce valid kernels. The simplest approach is
to use the sum of the diﬀerent kernels, which is equivalent
to taking the average kernel. This na¨ ıve combination has
been used mainly for comparison purposes. However, not
all data have equal quality and informativity. Depending
on the statistical and biological question at hand, data
from one source might contain more information than the
other. Moreover, the quality of data might vary because
of diﬀerent limitations and factors involved in diﬀerent
experiments. To our knowledge, currently there are no10 Human Genomics and Proteomics
published methods that explicitly incorporate quality and
informativity measures into the kernel framework.
There are few kernel-based statistical methods pro-
posed for integrating heterogeneous genomic data.
Lanckriet et al. [9] used kernel-based support vector
machine (SVM) method to recognize particular classes
of proteins—membrane proteins and ribosomal proteins.
Their method ﬁnds the classiﬁcation rule as well as the
corresponding weights for each data set. The performance
of the SVM trained on the combined data set is better than
that of the SVM trained on each of the individual data sets.
Moreover, the weights produced from the algorithm give
some measure of the relative importance of the diﬀerent
data sets. Another similar kernel-based approach was used
by Daemen et al. [4, 10]. They used kernel-based least
square support vector machine (LS-SVM) to combine
clinical and microarray data [10]. The same group applied
their method to combine microarray and proteomics data
[4]. They chose a standardized linear kernel for both data
sets in both papers. In the ﬁrst paper, leave-one-out cross
validation was performed on the training data set to get
optimal weights. The model based on the clinical and
microarray data performed slightly better than the model
based on each of the data sets alone. The performance of
their method was also compared with three conventional
clinical prognostic indices and was shown that the kernel-
based integrated microarray and clinical data outperforms
all three conventional approaches. In the second study,
the authors used the same method to combine microarray
and proteomic data to predict the response on cetuximab
in patients with rectal cancer. Tissue and plasma samples
were taken from the patients before treatment and at the
moment of surgery. Tissues were used for microarray
analysis and plasma samples were used for proteomics
analysis. They deﬁned four kernels from these data sets
and assigned equal weights to each one of them, that is, a
na¨ ıve combination of kernels was used. The method trained
on microarray data (with 5 genes) and protein data (10
proteins) performed better than any of the other alternatives
they considered.
4.4. Integrating Statistical Results with Biological Domain
Data. The ultimate purpose of statistical analysis on
genomic data is to gain some insight into the fundamental
biology. Annotation of statistical results helps biologists
in interpreting discovered patterns. A wide variety of
biological information is available to the public, such as
information on published literature on the topic of interest
(e.g., PubMed) and functional/pathway information (e.g.,
Gene Ontology, KEGG). Integrating biological information
with statistical results is, therefore, another important type
of data integration which can be considered as a bridge
between statistical results and biological interpretation.
Including biological domain data in statistical analysis can
be done at any stage of analysis. Al-Shahrour et al. [29], for
example, combined statistical results from gene expression
data with biological information in discovering molecular
functions related to certain phenotypes. Another popular
approach to incorporate prior biological knowledge into
statistical analysis is gene set enrichment analysis (GSEA)
[83, 84]. Given an a priori deﬁned set of genes, the goal
of GSEA is to determine whether a particular gene is
enriched or not, that is, whether members are randomly
distributed throughout or primarily found at the top or
bottom of a ranked list of gene diﬀerential expression
results.
There is also a rapidly growing list of computational and
visualization tools that can be used to integrate statistical
ﬁndings with biological domain information, and thereby
facilitating interpretation. For instance, packages from the
bioconductor project (www.bioconductor.org)p r o vi d ep o w -
erful analytical annotation and visualization tools for a wide
range of genetic and genomic data sets.
5. SummaryandFutureDirections
With a rapidly increasing amount of genomic, proteomic,
and other high throughput data, the importance of data
integration has increased signiﬁcantly. Biologists, medical
scientists, and clinicians are also interested to integrate
recently available high throughput data with already existing
clinical, laboratory, as well as prior biological information.
Moreover, data have been produced in various formats
(graphs, sequences, vectors, etc.) and dimensions and, as
a result, a simple merge of available data is not applicable
and in some cases impossible. Furthermore, data from
diﬀerent sources are subject to diﬀerent noise levels due to
diﬀerence in technologies, platforms and other systematic
or random factors aﬀecting the experiments. Consequently,
data might have diﬀerent qualities and a na¨ ıve combination
of data is not appropriate in such cases. The concept of
data informativity is also essential in any data integration
problem. Data from various sources might contain diﬀerent
informativity for a given statistical or biological task. One
data source might, for example, be more informative than
the other. A good data integration method should, therefore,
take these into account. Even if quality scoring has been used
in traditional statistical analysis, use of quality weights is not
common in genetics and genomics. Moreover, appropriate
qualityandinformativitymeasureshavenotbeendeﬁnedfor
many data types. An extensive research is, therefore, needed
in developing quality and informativity scores for various
genomic, genetic, and proteomic data.
In this paper, we proposed a conceptual framework for
genomic and genetic data integration. This framework, with
alittlemodiﬁcation,canalsobeusefulinanydataintegration
problem. The framework provides diﬀerent steps involved
in genomic data integration and addresses diﬀerent issues
and challenges. Moreover, putting current methodologies
for data integration under a single framework brings more
understanding in the research community. Furthermore, we
hopethatitwouldplayanimportantroleinthedevelopment
of standardized and improved data integration methods
that takes the quality, informativity, and other aspects of
individual data sets.Human Genomics and Proteomics 11
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